If You Could read My Mind – Wait, You Can?

By KIM BELLARD Over the years, one area of tech/health tech I have avoided writing about are brain-computer interfaces (B.C.I.). In part, it was because I thought they were kind of creepy, and, in larger part, because I was increasing finding Elon Musk, whose Neuralink is one of the leaders in the field, even more…

Read More

If You Could read My Mind – Wait, You Can?

By KIM BELLARD Over the years, one area of tech/health tech I have avoided writing about are brain-computer interfaces (B.C.I.). In part, it was because I thought they were kind of creepy, and, in larger part, because I was increasing finding Elon Musk, whose Neuralink is one of the leaders in the field, even more…

Read More

Quantifying treatment value under IRA

That is the title of my new publication out today with the subtitle “A case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures“. This was work with co-authors Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, Sanjana Muthukrishnan, and Aditi Chaudhary. The abstract is below. BackgroundTraditional cost effectiveness analyses…

Read More

Medicare Drug Price Negotiation Results: 2027

Today, the Centers for Medicare and Medicaid Services (CMS) released the results from the Medicare Drug Price Negotiation Program for Initial Price Applicability Year (IPAY) 2027 (press release). What was the average reduction in drug prices? Across the 15 drugs included in the 2027 negotiation, on average, drug prices fell by 62% (median: 63%); accounting…

Read More